191 related articles for article (PubMed ID: 9079825)
1. Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides.
Bertholet S; Iggo R; Corradin G
Eur J Immunol; 1997 Mar; 27(3):798-801. PubMed ID: 9079825
[TBL] [Abstract][Full Text] [Related]
2. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.
Yanuck M; Carbone DP; Pendleton CD; Tsukui T; Winter SF; Minna JD; Berzofsky JA
Cancer Res; 1993 Jul; 53(14):3257-61. PubMed ID: 7686815
[TBL] [Abstract][Full Text] [Related]
3. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
[TBL] [Abstract][Full Text] [Related]
4. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H
Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253
[TBL] [Abstract][Full Text] [Related]
5. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.
Houbiers JG; Nijman HW; van der Burg SH; Drijfhout JW; Kenemans P; van de Velde CJ; Brand A; Momburg F; Kast WM; Melief CJ
Eur J Immunol; 1993 Sep; 23(9):2072-7. PubMed ID: 8370389
[TBL] [Abstract][Full Text] [Related]
6. CTL escape viral variants. I. Generation and molecular characterization.
Lewicki H; Tishon A; Borrow P; Evans CF; Gairin JE; Hahn KM; Jewell DA; Wilson IA; Oldstone MB
Virology; 1995 Jun; 210(1):29-40. PubMed ID: 7793078
[TBL] [Abstract][Full Text] [Related]
7. Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif.
Lipford GB; Hoffman M; Wagner H; Heeg K
J Immunol; 1993 Feb; 150(4):1212-22. PubMed ID: 7679422
[TBL] [Abstract][Full Text] [Related]
8. Induction of CTL in vivo by major histocompatibility complex class I-peptide complexes covalently associated on the cell surface.
Anjuère F; Horvath C; Cerottini JC; Luescher IF
Eur J Immunol; 1995 Jun; 25(6):1535-40. PubMed ID: 7614979
[TBL] [Abstract][Full Text] [Related]
9. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses.
De Bruijn ML; Schumacher TN; Nieland JD; Ploegh HL; Kast WM; Melief CJ
Eur J Immunol; 1991 Dec; 21(12):2963-70. PubMed ID: 1660811
[TBL] [Abstract][Full Text] [Related]
10. Presentation of a horse cytochrome c peptide by multiple H-2b class I major histocompatibility complex (MHC) molecules to C57BL/6- and bm1-derived cytotoxic T lymphocytes: presence of a single MHC anchor residue may confer efficient peptide-specific CTL recognition.
Sheil JM; Schell TD; Shepherd SE; Klimo GF; Kioschos JM; Paterson Y
Eur J Immunol; 1994 Sep; 24(9):2141-9. PubMed ID: 7522163
[TBL] [Abstract][Full Text] [Related]
11. Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules.
Shirai M; Pendleton CD; Berzofsky JA
J Immunol; 1992 Mar; 148(6):1657-67. PubMed ID: 1371784
[TBL] [Abstract][Full Text] [Related]
12. Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte.
Frassanito MA; Mayordomo JI; DeLeo RM; Storkus WJ; Lotze MT; DeLeo AB
Cancer Res; 1995 Jan; 55(1):124-8. PubMed ID: 7528638
[TBL] [Abstract][Full Text] [Related]
13. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
[TBL] [Abstract][Full Text] [Related]
14. Immunization with synthetic peptides containing a defined malaria epitope induces a highly diverse cytotoxic T lymphocyte response. Evidence that two peptide residues are buried in the MHC molecule.
Romero P; Eberl G; Casanova JL; Cordey AS; Widmann C; Luescher IF; Corradin G; Maryanski JL
J Immunol; 1992 Mar; 148(6):1871-8. PubMed ID: 1541825
[TBL] [Abstract][Full Text] [Related]
15. Induction and characterization of minor histocompatibility antigens. Specific primary cytotoxic T lymphocyte responses in vitro.
Ando K; Nakashima I; Nagase F; Isobe K; Kawashima K; Hasegawa Y; Yoshida T; Iwamoto T; Hasegawa T; Muro Y
J Immunol; 1988 Feb; 140(3):723-9. PubMed ID: 2448374
[TBL] [Abstract][Full Text] [Related]
16. T lymphocyte responses to multiple minor histocompatibility antigens generate both self-major histocompatibility complex-restricted and cross-reactive cytotoxic T lymphocytes.
Tremblay N; Fontaine P; Perreault C
Transplantation; 1994 Jul; 58(1):59-67. PubMed ID: 8036709
[TBL] [Abstract][Full Text] [Related]
17. A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells.
Lacabanne V; Viguier M; Guillet JG; Choppin J
Eur J Immunol; 1996 Nov; 26(11):2635-9. PubMed ID: 8921949
[TBL] [Abstract][Full Text] [Related]
18. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
19. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay.
Stuber G; Leder GH; Storkus WT; Lotze MT; Modrow S; Székely L; Wolf H; Klein E; Kärre K; Klein G
Eur J Immunol; 1994 Mar; 24(3):765-8. PubMed ID: 8125143
[TBL] [Abstract][Full Text] [Related]
20. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells.
Yu Z; Liu X; McCarty TM; Diamond DJ; Ellenhorn JD
J Surg Res; 1997 May; 69(2):337-43. PubMed ID: 9224403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]